LB Pharmaceuticals Inc (LBRX)
LBRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$34.79
-3.17% on the day
Market cap
$1.1B
Small cap
Revenue
Recent IPO: no annual report filed yet
Net income
Recent IPO: no annual report filed yet
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | LBRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0001691082 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Recent IPO: no annual report filed yet.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-10-01 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-09-15 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 141 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.1% |
| 1 month | -20.6% |
| 3 months | +11.7% |
| Year to date | +53.5% |
| 1 year | +112.7% |
| From 52-week high | -30.9% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $31.68 | -6.96% | $1.1B |
| AMPH | Amphastar Pharmaceuticals Inc. | $26.05 | -2.65% | $1.1B |
| DMRA | Damora Therapeutics Inc. | $18.56 | -8.37% | $1.1B |
| BCAX | Bicara Therapeutics Inc. | $17.34 | +0.06% | $1.1B |
| NBTX | Nanobiotix S.A. | $21.49 | -8.16% | $1.1B |
| ORIC | Oric Pharmaceuticals Inc. | $11.31 | -4.23% | $1.2B |
| HROW | Harrow Inc. | $28.24 | -2.99% | $1.1B |
| AVLN | Avalyn Pharma Inc. | $23.74 | -4.27% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier